NCT00077415View on ClinicalTrials.gov

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Lung Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

triapine

Trial Locations (8)

2050

Sydney Cancer Centre at Royal Prince Alfred Hospital, Sydney

6009

Sir Charles Gairdner Hospital - Perth, Perth

119074

Cancer Institute at National University Hospital, Singapore

119260

National University of Singapore, Singapore

169610

National Cancer Centre - Singapore, Singapore

308433

Johns Hopkins Singapore International Medical Centre, Singapore

Unknown

Prince of Wales Hospital, Shatin, New Territories

120-752

Yonsei Cancer Center at Yonsei University Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Cancer Therapeutics Research Group

OTHER